DHR and WAT Related Headlines
Go Back- KeyBanc's Preview of 'Biggest Potential Beats in Life Science'
- Morgan Stanley sees Waters best positioned after China lab pricing rules
- Evercore: ' Latest Survey Work Positions 2026 As Better Year For Biopharma Spending'
- KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
